Efficacy and safety of endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors (TKI) after programmed cell death 1 (PD-1) inhibitor treatment in patients with metastatic clear cell renal cell carcinoma (mccRCC) Meeting Abstract

  

Authors:	Nadal, R.; Amin, A.; Geynisman, D. M.; Voss, M. H.; Weinstock, M.; Doyle, J.; Zhang, Z.; Viudez, A.; Plimack, E. R.; McDermott, D. F.; Motzer, R.; Rini, B. I.; Hammers, H. J.
Abstract Title:	Efficacy and safety of endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors (TKI) after programmed cell death 1 (PD-1) inhibitor treatment in patients with metastatic clear cell renal cell carcinoma (mccRCC)
Meeting Title:	51st Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	33
Issue:	15 Suppl.
Meeting Dates:	2015 May 29-Jun 2
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2015-05-20
Language:	English
ACCESSION:	WOS:000358036901037
PROVIDER:	wos
DOI:	10.1200/jco.2015.33.15_suppl.4566
Notes:	Meeting Abstract: 4566 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/80529